Affiliation:
1. POLTAVA STATE MEDICAL UNIVERSITY, POLTAVA, UKRAINE
Abstract
Aim: To carry out a comprehensive evaluation of treatment modification for patients with seasonal allergic rhinitis (SAR) complicated by anxiety-neurotic disorders.
Materials and Methods: Patients with SAR in the acute stage on the background of anxiety disorders were studied. Immunological studies were carried out, an assessment of the dynamics of indicators of the quality of life of patients, the level of anxiety / depression was assessed. In the clinical group, a variant of therapy modification was proposed.
Results: Significant changes in the subpopulation ratio of lymphocytes, an increase in the immunoregulatory index, which indicated the severity of the immunological process, were revealed in SAR patients in the acute stage against the background of anxiety disorders. At the same time, a significant activation of the humoral link of immunity was observed: an increase and a significant increase in IgE in the blood serum and an increase in the content of sIgA in the nasal secretion. In most patients, eosinophilia was found in the peripheral blood and in the rhinocytogram before treatment. In the study of the quality of life of patients, changes in many parameters were found.
Conclusions: The combination of “Nazafort Allergy Protection” and Atarax seems to be the most successful, which significantly improved the physical and psycho-emotional state of patients with SAR, complicated by anxiety and neurotic disorders. This combination led to an increase in the stress resistance of patients.
Reference18 articles.
1. 1. Knight J, Nigam Y. The lymphatic system 4: allergies, anaphylaxis and anaphylactic shock. Nursing Times. 2021; 117(1): 54–58.
2. 2. Fokkens WJ, Lund VJ, Hopkins C et al. European Position Paper on Rhinosinusitis and Nasal Polyps. Rhinology. 2020;58 (29): 1–464. doi: 10.4193/Rhin20.600. DOI
3. 3. Emeryk A, Maksymiuk J, Janeszek K. New guidelines for the treatment of seasonal allergic rhinitis. Postepy Dermatol Alergol. 2019; 36(3): 255–260. doi: 10.5114/ada.2018.75749. DOI
4. 4. Chistik T. Suchasni mozhlyvosti antyhistaminnoyi terapiyi alerhichnoho rynitu ta kropyv"yanky [Modern possibilities in the treatment of allergic rhinoconjunctivitis and urticaria: focus on bilastine (NixarR)]. News of Medicine and Pharmacy. 2016;5(574): 3–4. (in Ukrainian).
5. 5. Brożek JL, Bousquet J, Agache I et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J. Allergy Clin. Immunol. 2017;140(4): 950–958.